Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Human Genome Sciences, Inc. (HGSI) -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (1089)	8/25/2009 10:04:59 AM
From: kenhott	Read Replies (2) \| Respond to of 1127

I have heard a couple of rumors about a takeout of HGSI also. I am putting a little cash on the line that it won't happen till after the 2nd phase 3, if it does. People can think what they want, but I don't see the 2nd phase 3 as a cakewalk. At $30/share, $5B is more than pocket change even for big pharma. Someone has to stand in front of the board and explain what happens if the 2nd phase 3 bombs.

To: rkrw who wrote (1089)	8/25/2009 11:26:06 AM
From: Steven Rachbach	Read Replies (2) \| Respond to of 1127

IMO, the main purpose of a GSK buyout would to acquire full rights to the Lp-PLA2 drugs. HGSI stands to get a 10% royalty off the top with a 20% co-promote option for a measly 20% of promotion costs. The huge P3 for the drug has gone for 7 months now and GSK gets peeks at the data. If the drug passes the P3, it would be the next Lipitor. Add to that the other 50% of profits for Benlysta and a 2 Billion carry forward loss..